Abstract：
Hematological and neurological expressed 1 (HN1), also known as Jupiter microtubule associated homolog 1 (JPT1), is a highly conserved protein with widespread expression in various tissues. Ectopic elevation of HN1 has been observed in multiple cancers, highlighting its role in tumorigenesis and progression. Both proteomics and transcriptomics reveal that HN1 is closely associated with severe disease progression, poor prognostic and shorter overall survival. HN1\'s involvement in cancer cell proliferation and metastasis has been extensively investigated. Overexpression of HN1 is associated with increased tumor growth and disease progression, while its depletion leads to cell cycle arrest and apoptosis. The pivotal role of HN1 in cancer progression, particularly in proliferation, migration, and invasion, underscores its significance in cancer metastasis. Validation of the efficacy and safety of HN1 inhibition, along with the development of diagnostic methods to determine HN1 expression levels in patients, is essential for the translation of HN1-targeted therapies into clinical practice. Overall, HN1 emerges as a valuable prognostic marker and therapeutic target in cancer, and further investigations hold the potential to improve patient outcomes by impeding metastasis and enhancing treatment strategies.
摘要：
血液学和神经学表达1（HN1），也被称为木星微管相关同源物1(JPT1)，是一种高度保守的蛋白质，在各种组织中广泛表达。在多种癌症中观察到HN1的异位升高，强调其在肿瘤发生和发展中的作用。蛋白质组学和转录组学都表明HN1与严重的疾病进展密切相关。预后较差，总生存期较短。HN1与癌细胞增殖和转移的关系已得到广泛研究。HN1的过表达与肿瘤生长和疾病进展增加有关，而其耗尽导致细胞周期停滞和细胞凋亡。HN1在癌症进展中的关键作用，特别是在扩散方面，迁移,和入侵,强调了其在癌症转移中的重要性。HN1抑制的有效性和安全性的验证，随着确定患者HN1表达水平的诊断方法的发展，对于将HN1靶向治疗转化为临床实践至关重要。总的来说,HN1作为癌症的一个有价值的预后标志物和治疗靶点，进一步的研究认为,有可能通过阻止转移和加强治疗策略来改善患者的预后.
